Skip Ribbon Commands
Skip to main content
Skip over global navigation links
U.S. Department of Health and Human Services


ASPR Frequently Asked Questions:

  1. What is an oral antiviral?

Oral antivirals are used to treat chronic or severe viral infections that cannot be eliminated by an individual’s natural immune response. Antivirals can function in a variety of ways to treat a virus, depending on the therapy and virus type.

  1. Who is eligible for this treatment?

Molnupiravir is authorized for the treatment of mild to moderate COVID-19 in adults age 18 years and older, who are at high risk for progressing to severe COVID-19 and for whom alternative COVID-19 treatment options are not accessible or clinically appropriate. Pregnant individuals or women who may become pregnant should speak with a healthcare provider regarding any treatment limitations.

  1. Do I need a prescription from a healthcare provider to receive treatment?

Yes; a prescription from a qualified healthcare provider is required to be treated with Molnupiravir.

  1. How will the U.S. Department of Health and Human Services determine how much Molnupiravir is allocated to state and territorial health departments?

Initial allocations were determined on a pro rata basis (based on adult population) and will be provided to state and territorial health departments for free.

A subset of HHS Health Resources Services Administration (HRSA)-funded health centers across all 50 states will also receive direct product allocation to help increase equitable access to this product in vulnerable and hard-hit communities.

  1. Is Molnupiravir available now?

State and territorial health departments can order product now through the HHS Health Partners Ordering Portal. Dispensing sites will begin to receive product by the end of December.

  • This page last reviewed: January 04, 2022